Shares of Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) have received an average recommendation of “Hold” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $4.4167.
SGHT has been the subject of several recent research reports. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research report on Thursday, August 28th. Wall Street Zen upgraded shares of Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Citigroup boosted their target price on shares of Sight Sciences from $3.60 to $4.50 and gave the company a “neutral” rating in a research report on Thursday, August 21st. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price target (up from $3.50) on shares of Sight Sciences in a research report on Wednesday, June 18th. Finally, Morgan Stanley upped their price target on shares of Sight Sciences from $3.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th.
Get Sight Sciences alerts:
Check Out Our Latest Stock Analysis on SGHT
Hedge Funds Weigh In On Sight Sciences
A number of hedge funds have recently modified their holdings of SGHT. CWM LLC boosted its position in shares of Sight Sciences by 70.2% in the second quarter. CWM LLC now owns 7,607 shares of the company’s stock worth $31,000 after purchasing an additional 3,137 shares during the period. ProShare Advisors LLC bought a new position in shares of Sight Sciences in the fourth quarter worth approximately $36,000. Tower Research Capital LLC TRC boosted its position in shares of Sight Sciences by 32.7% in the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares during the period. Bank of Montreal Can bought a new position in shares of Sight Sciences in the second quarter worth approximately $49,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in shares of Sight Sciences by 38.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock worth $66,000 after acquiring an additional 4,453 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.
Sight Sciences Stock Performance
Shares of NASDAQ SGHT opened at $3.35 on Thursday. The firm has a 50 day moving average of $3.75 and a 200 day moving average of $3.46. The company has a current ratio of 10.01, a quick ratio of 9.49 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $175.44 million, a price-to-earnings ratio of -3.49 and a beta of 2.42. Sight Sciences has a 12-month low of $2.03 and a 12-month high of $6.29.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $19.56 million during the quarter, compared to analyst estimates of $18.18 million. Sight Sciences had a negative net margin of 64.23% and a negative return on equity of 59.38%. Sight Sciences has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Sight Sciences will post -0.99 earnings per share for the current year.
About Sight Sciences
(Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company’s products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Further Reading
Five stocks we like better than Sight Sciences
Retail Stocks Investing, Explained
Datavault AI: The New AI Contender Backed by Big Funding
Insider Trading – What You Need to Know
CoreWeave: Why the New King of AI Infrastructure Has Room to Run
3 Warren Buffett Stocks to Buy Now
Top 3 Dividend Achievers for October: High Yields, Growth Ahead